Logotype for Merck KGaA

Merck (MRK) investor relations material

Merck Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Merck KGaA
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Q3 net sales rose 5.8% YoY to €5.627bn, with 5.1% organic growth; EBITDA pre increased 0.8% to €1.682bn. Growth was led by Life Science and Electronics.

  • FY 2026 guidance was raised for net sales, EBITDA pre and free cash flow, while reported earnings were pressured by a €366m CDMO impairment.

Financial highlights

  • Q3 reported sales growth comprised 5.1% organic growth, a 1.5-point FX contribution and a 0.8-point negative portfolio effect.

  • EBITDA pre was €1.682bn versus €1.669bn, up 0.8% reported and 0.4% organically; EPS pre was €2.32, unchanged YoY.

  • EBIT fell to €653m from €1.221bn; profit after tax was €450m versus €898m, and reported EPS was €1.04 versus €2.07.

  • Operating cash flow rose 9.4% to €1.660bn and free cash flow increased 22.7% to €1.317bn.

  • 9M sales rose 2.2% to €16.195bn; EBITDA pre increased 3.1% to €4.811bn and EPS pre rose 2.0% to €6.59.

Outlook and guidance

  • FY 2026 net sales guidance: €21.5bn–€21.9bn, with organic growth of 3%–4% and FX impact of -1% to 0%; EBITDA pre guidance: €6.2bn–€6.4bn, with organic growth of 3%–5%.

  • EPS pre guidance is €8.30–€8.70; free cash flow guidance increased to €2.3bn–€2.7bn.

  • Guidance assumes Bio-Techne contributes in December 2026 and no U.S. Mavenclad sales from November; EBITDA pre FX impact is forecast at -2% to 0%.

  • Segment sales guidance: Life Science €9.4bn–€9.6bn, Healthcare €8.5bn–€8.7bn and Electronics ~€3.6bn; Electronics organic growth guidance is 10%–11%.

  • FY 2026 capex on PPE is guided at €1.3bn–€1.5bn; the underlying tax rate is expected at 22%–24% from 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Merck earnings date

Logotype for Merck KGaA
ESG update8 Dec, 2026
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Merck earnings date

Logotype for Merck KGaA
ESG update8 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. The company's Life Science business segment focuses on the development, manufacture, marketing and distribution of pharmaceutical products. It offers drugs for a range of therapeutic indications from central nervous system diseases to cardiovascular and metabolic disorders. In addition to its own pharmaceutical activities, MERCK helps develop medicines for customers. The company also participates in the development of active substances with partners.